Aerosol Delivery of Palivizumab in a Neonatal Lamb Model of Respiratory Syncytial Virus Infection

(1) Background: Palivizumab has been an approved preventative monoclonal antibody for respiratory syncytial virus (RSV) infection for over two decades. However, due to its high cost and requirement for multiple intramuscular injections, its use has been limited mostly to high-income countries. Follo...

Descripción completa

Detalles Bibliográficos
Autores principales: Edirisinghe, Hasindu S., Rajapaksa, Anushi E., Royce, Simon G., Sourial, Magdy, Bischof, Robert J., Anderson, Jeremy, Sarila, Gulcan, Nguyen, Cattram D., Mulholland, Kim, Do, Lien Anh Ha, Licciardi, Paul V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10675108/
https://www.ncbi.nlm.nih.gov/pubmed/38005952
http://dx.doi.org/10.3390/v15112276

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10675108/
https://www.ncbi.nlm.nih.gov/pubmed/38005952
http://dx.doi.org/10.3390/v15112276

Ejemplares similares